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Introduction 62
Cryptococcus gattii and Cryptococcus neoformans are the two major Cryptococcus species that 63 cause clinical infections in humans [1] due to the ability of basidiomycetous yeasts to grow at 64 37°C through asexual yeast budding in human and animal hosts. Upon inhalation of infectious 65 propagules, Cryptococcus spp. penetrate the lung tissue and reproduce, causing pulmonary 66 cryptococcosis, leading to the possibility of dissemination to other organs, most commonly the 67 brain [2] . C. gattii infections occur in both immunocompetent and immunocompromised 68 individuals, whereas C. neoformans infections are more common in immunosuppressed 69 patients, such as those who have received organ transplants or have HIV infection/AIDs or 70 hematological malignancies [3] . In mice infected with C. neoformans, CD4 + T-helper 1 (Th1) 71 cells play an important role in fighting infection as demonstrated by the fact that interferon 72 (IFN)-γ and interleukin (IL)-12-knockout mice had a higher mortality index than did mice 73 wild-type for . In addition, mice infected with C. gattii displayed reduced 74 dendritic cell-mediated Th1/Th17 immune responses [8] . Although several fungal vaccine 75 studies have demonstrated an essential role for CD8 + T cells in destroying host cells harboring 76 intracellular fungus [9] , not many studies have used CD8+ T cells for direct killing of 77 extracellular fungal infection. 78
Our group was the first to explore the direct killing of extracellular fungi through the 79 redirection of CD8 + T cells via expression of an engineered chimeric antigen receptor (CAR) 80 to target a carbohydrate expressed on fungal cell walls [9, 10] . CARs are usually composed of 81 four domains: 1) an extracellular antigen specific binding domain or domains, 2) a hinge or 82 spacer region, 3) a transmembrane region, and 4) a cytoplasmic signaling region [11, 12] . 83
Interest in using CAR + T cells to treat diseases such as cancer has increased in recent years 84 because CAR-based recognition enables T cells to identify proteins, glycoproteins, or 85 glycolipids on the cell surface and release cytotoxic proteins which destroy the target cells in 86 a manner that does not depend on the peptide-major histocompatibility complex expressed on 87 antigen-presenting cells (APCs) [13] . CAR-dependent T-cell activation is achieved through the 88 CAR endodomain, which is composed of CD28 or CD137 and CD3- [14, 15] . In most studies 89 using CARs, researchers have administered CD19-targeted CARs for the treatment of B-cell 90 malignancies. Recently, the U.S. Food and Drug Administration approved CAR + T-cell 91 therapies for leukemia and lymphoma [13, [16] [17] [18] [19] [20] . We demonstrated that T cells expressing a 92 CAR containing the extracellular portion of Dectin-1 (D-CAR) targeted germinating fungal 93 hyphae and inhibited hyphal growth of Aspergillus spp. [10] . However, the direct 94
Cryptococcus-killing activity of CD8 + T cells has yet to be widely explored in the development 95 of immunotherapy for infections with this pathogen. 96
Fungal cell wall glycans and exopolysaccharides are the first point of physical contact 97 in fungal-host interactions, and these polysaccharides are common to multiple fungi [21] . 98
Pattern recognition receptors present on innate immune cells recognize these glycans and 99 eliminate fungal spores, germinating hyphae, and yeast. However, Cryptococcus spp. has 100 exopolysaccharides that can mask these glycans that are recognized by immune cells. In the 101 present study, we adapted a CAR to redirect engineered CD8 + T cells to target the 102 polysaccharide capsule of Cryptococcus spp. The capsule of Cryptococcus spp. is a major 103 virulence factor primarily composed of the sugar moiety glucuronoxylomannan (GXM), with 104 lesser amounts of galactoxylomannan (GalXM) and mannoproteins [22] [23] [24] . One of the 105 functions of the capsule is to provide protection from the recognition by the host immune 106 system, which can be achieved by means such as preventing recognition and phagocytosis by To generate the GXMR-CAR construct, the DNA sequence of the GXM-specific scFv 135 (scFv-18B7) was fused to modified human IgG4 hinge and Fc regions, transmembrane and co-136 stimulatory domains of CD28, and the signaling domain of CD3- ( Fig 1A) as reported 137 previously [10] . HEK-293FT cells were used to make GXMR-CAR + viral particles by 138 transfecting them with three plasmids: pMD2.G for the envelope, psPAX2 for packaging, and 139 GXMR-CAR, according to the manufacturer's instructions as described in the Materials and 140 Methods section. The success of transfection was determined by analyzing green fluorescent 141 protein (GFP) expression after 24 h ( Fig 1B) at 100× and 200× magnification. 142 After the viral particles containing GXMR-CAR were generated, HEK-293FT cells 143
were infected with the particles to evaluate the GXMR-CAR transduction efficiency. After 144 three days in culture, the GFP positive cells were identified by using fluorescence microscopy 145 ( Fig 1C, right) . and the GFP expression in transduced cells was quantified using flow cytometry 146 ( Fig 1C, left) A high efficiency of transduction of HEK-293FT cells with GXMR-CAR + viral 147 particles was observed, as 67% of the cells were GFP + ( Fig 1C) . 148
149

GXMR-CAR expression on human T cells 150
After GXMR-CAR was successfully expressed in HEK-293FT cells, the same protocol was 151 utilized for the transduction of human T cells. Initially, peripheral blood mononuclear cells 152 (PBMCs) were stimulated with an antibody cocktail (anti-CD3/CD28) combined with IL-2 for 153 3 days. Activated human T cells were transduced with GXMR-CAR + viral particles and after 154 3 days post-transduction, GXMR-CAR + T cells were enriched by sorting based on GFP 155 expression, and expansion of GXMR-CAR + T cells was performed as described in Materials 156 and Methods. After 3 days of expansion, 82.4% of the human GXMR-CAR + T cells expressed to the spacer region of IgG4 (as shown in Fig 1A) localized on their surface. The results show 160 that 77.8% of the GXMR-CAR + T cells were positive for the antibody (Fig 2B) , confirming 161 the expression of GXMR-CAR on the T-cell surface. Expanded GXMR-CAR + T cells were 162 evaluated by flow cytometry to determine if the stem cell memory, central memory, and 163 effector memory T-cell subsets, which are critical for long-term immune memory, were 164 prevalent in GXMR-CAR + T cells (Fig 2 C, D) . 165
166
GXMR-CAR + T cells interact with soluble GXM from the Cryptococcus spp. capsule 167
To determine whether GXMR-CAR + T cells recognize GXM polysaccharide from 168
Cryptococcus spp., GXMR-CAR + T cells were incubated with a preparation of polysaccharide 169 antigens from the capsule of Cryptococcus spp. After 24h of incubation with polysaccharide 170 antigens from Cryptococcus spp., cell clusters were observed by bright-field microscopy in 171 wells treated with GXMR-CAR T cells, while no cell clusters were detected upon incubation 172 of NoDNA T cells (mock transduced cells) with the polysaccharide antigen ( Fig 3A) . Similar 173 types of cell clusters were observed in the anti-CD3/CD28 antibody treated positive control, 174 while no cell clusters were observed in the medium alone negative control wells ( Fig 3A) . 175
These results suggest that GXMR-CAR + T cells interact with polysaccharide antigens in the 176 capsule of Cryptococcus spp., promoting the clustering of GXMR-CAR + T cells. 177
The recognition of GXM by GXMR-CAR + T cells allowed to investigate whether 178 GXMR-CAR + T cells target C. neoformans yeast. The C. neoformans yeast was stained with 179
Calcofluor-white (blue), and incubated with GXMR-CAR + T cells (green) or NoDNA T cells 180 (negative control; green), and their interaction was visualized using fluorescence microscopy. 181
The results show that GXMR-CAR + T cells co-localized with C. neoformans yeast ( Fig 3B,  182 right), while the NoDNA T cells did not interact with the yeast (Fig 3B, left) . Moreover, in 183 GXMR-CAR + T cell-treated wells, C. neoformans yeast was trapped inside T-cell clusters, 184 whereas in wells with NoDNA T cells, the cells did not interact with the yeast, and no cell 185 clusters were observed. These results demonstrate that GXMR-CAR + T cells can recognize 186
Cryptococcus spp. yeast and form complexes with it. To corroborate these findings, additional 187 experiments were conducted to determine the specificity of GXMR-CAR + T cells for GXM. 188
Polysaccharide antigens from the capsule of Cryptococcus spp. were incubated with GXMR-189 CAR + T cells, and an anti-GXM mAb 18B7 was added to detect GXM on the surface of 190 GXMR-CAR + T cells using flow cytometry ( Fig 3C, right) . The recognition of soluble GXM 191 by GXMR-CAR + T cells was demonstrated by cells that were double-positive for and the anti-GXM mAb 18B7 clone ( Fig 3C) , whereas NoDNA T cells did not recognize GXM. 193 These findings confirmed that the GXMR-CAR-expressing T cells targeted GXM, a major 194 compound in the Cryptococcus spp. capsule. 195
196
Targeting efficacy of GXMR-CAR + T cells in a pulmonary Cryptococcus infection model 197
NOD Scid gamma (NSG) mice were used for these studies because they are deficient in mature 198 B, T, and natural killer cells. Therefore, they are unable to target and destroy infused GXMR-199 CAR + T cells. Pulmonary fungal infection was established in the mice by infecting their lungs 200 with C. neoformans yeast (1 × 10 5 /mouse) via intranasal infusion [28] . The mice were placed 201 into 3 groups according to the infusions they received: GXMR-CAR + T cells, NoDNA T cells, 202 and phosphate-buffered saline (PBS). The mice were infused with 5 million GXMR-CAR + T 203 cells, NoDNA T cells, or PBS alone via tail vein injection at 1 and 4 days after infection. Eight 204 days after infection, the mice were humanely euthanized and entire sections of lung tissue were 205 evaluated by immunofluorescence using an anti-GXM antibody and imaging was performed at 206 400x ( Fig. 4A ). More than 2000 images were analyzed using the automated inForm ® Cell 207 Analysis ™ software to quantify the area of GXM-FITC stained Titan cells ( Fig. 4B , red shaded 208 region) and total area of lung tissue (green shaded region) on each slide. A smaller area of 209 GXM positive Titan cells (hallmark of Cryptococcus infection in the lung) was observed in the 210 GXMR-CAR samples (0.021 mm 2 GXM, 57.55 mm 2 lung) compared to the negative controls 211 (PBS: 0.37 mm 2 GXM, 39.2 mm 2 lung; NoDNA: 0.066 mm 2 GXM, 60.0 mm 2 lung), indicating 212 a reduced fungal burden due to treatment with GXMR-CAR + T cells (Fig 4) . These results 213 were supported by Gomori methenamine-silver (GMS) staining of Titan cells in lung tissue 214 sections obtained from the mice in the PBS, GXMR-CAR + T-cell, and NoDNA T-cell groups. 215 A lower fungal burden was observed in the GXMR-CAR + T-cell group compared with the PBS 216 group ( Fig 4C) . In addition, ImageJ was used to analyze the nine anti-GXM 217 immunofluorescence images shown in Fig 5A, and determine the area of GXM positive 218 staining in the lung tissues. Figure S1 shows some of the processing steps involved in 219 processing the images using ImageJ. The ImageJ analysis demonstrated a significant reduction 220 in the area of GXM staining in the GXMR-CAR T cell treated group compared to the PBS 221 control. Corroborating our in vitro results, these data demonstrate that intravenously infused 222 GXMR-CAR + T cells directly target C. neoformans and control its spread in the lungs of 223 Kumaresan et al. [10] . In the present study, we are 233 the first group to develop CAR + T cells targeting the yeast virulence factor GXM, a 234 carbohydrate present in the Cryptococcus spp. capsule. The extracellular domain of GXMR-235 CAR + T cells was derived from the murine mAb 18B7, which binds to GXM and has a high 236 affinity for Cryptococcus spp. In a phase I dose escalation trial, researchers tested treatment of 237 cryptococcal meningitis in HIV + patients with 18B7 [26, 27] . They observed transient 238 decreases in serum cryptococcal antigen levels in patients receiving 18B7 doses of 1-2 mg/kg 239 and that doses up to 1 mg/kg were well tolerated. However, the use of CAR T cell therapy has 240 not been explored for treating cryptococcosis. We designed GXMR-CAR as a second-241 generation CAR with a similar structure to CD19RCAR, which has undergone in clinical trials 242 (www.clinicaltrials.gov, NCT01318317 and NCT01815749), except that the scFv domain, 243 which targets GXM, was swapped with the scFv that targets CD19. The lentiviral vector that 244 was used for genomic insertion of CAR constructs was selected because (1) Another immunomodulatory treatment strategy is adoptive T-cell therapy, which can 279 induce cell-mediated immunity against invasive fungal infections. CD4 + T cells differentiate 280 into Th1 and Th17 cells that mainly secrete IFN- and IL-17, respectively, activating innate 281 immune cells to fight fungal infections [36, 37] . In addition, the proinflammatory cytokines 282 produced by Th1 and Th17 cells activate B cells, resulting in the secretion of antigen-specific 283 antibodies against fungi. Moreover, CD8 + T cells differentiate into Tc1 and Tc17 cells, which 284 produce IFN- and IL-17, contributing to the recruitment of innate immune cells involved in 285 antifungal defense. The major mechanism that CD8 + T cells use to control fungal infections is 286 the targeted release of cytotoxic factors that act directly on fungi, such as perforin, granulysin, 287 and granzyme [9] . The antifungal activity of adoptive T-cell therapy can be improved by 288
redirecting T-cell specificity using a CAR that recognizes specific fungal antigens. In this 289 context, Kumaresan et al. [10] demonstrated that engineered CAR + T cells containing an 290 extracellular domain of the carbohydrate recognition domain of Dectin-1 (D-CAR-expressing 291 T cells) were capable of targeting -glucan-expressing fungi. In vitro and in vivo studies 292 showed that D-CAR-expressing T cells target germinating Aspergillus hyphae and inhibit 293 aspergillosis dissemination by using the cytolytic machinery of the genetically modified T cells 294 [10] . 295
These findings led us to develop CAR + T cells expressing an scFv from the mAb 18B7 296 to target Cryptococcus spp. that contain a polysaccharide capsule predominantly comprised of 297 GXM [38] . Because the compounds in the Cryptococcus spp. capsule impair the recognition 298 of pathogen-associated molecular patterns by pattern recognition receptors, the -glucans, 299 mannoproteins, and chitin are poorly recognized by the immune system. GXMR-CAR 300 expressed on human T cells recognizes the soluble form of GXM and targets C. neoformans 301 yeast, demonstrating the specificity of GXMR-CAR to this pathogen. The major fungi 302 responsible for invasive fungal infections, Candida and Aspergillus species, lack GXM and 303 have different polysaccharide compositions in the outer cell wall [21] , while GXMR-CAR 304 specifically targets only fungi that have GXM in the outer cell wall. Our in vivo studies 305 demonstrated that GXMR-CAR + T cells efficiently reduced the number of Titan cells in the 306 lungs of mice infected with C. neoformans when compared to the negative control group, as 307 demonstrated by immunofluorescence and histochemistry (Fig 4) . These findings show that 308 GXMR-CAR + T cells can directly target Cryptococcus spp. in the lungs. GXMR-CAR + T cells 309 may reduce the severity of Cryptococcus spp. infection in the lungs (Fig. 5 ) through the 310 following mechanisms: 1) production of TNF-α and IFN- augmenting the response of APCs 311 and neutrophils against to Cryptococcus spp.; 2) release of granzyme, granulysin, and perforin 312 by GXMR-CAR + T cells, which may cause the degradation of Cryptococcus spp. cell walls; 3) 313 secretion of cytokines and chemokines from GXMR-CAR + T cells, which can cause epithelial 314 cells (mucosal immunity) to produce antimicrobial peptides; and 4) fungal breakdown products 315 taken in by dendritic cells may be cross-presented to T cells and activate humoral immunity. 316
Our new approach to targeting Cryptococcus spp. with CAR + T cells using an anti-GXM mAb 317 may be extended to other invasive fungal infections using monoclonal antibodies specific to 318 other cell wall proteins. This pioneering effort highlights the first use of CAR + T cells designed 319 to target Cryptococcus spp. 320
Cytokine release syndrome (CRS) and macrophage activating syndrome are the major 321 limiting factors for CAR cell mediated immunotherapy. Clinicians have developed strategies 322 to address CRS, such as treatment with Tocilizumab, an antibody to IL6R that blocks binding 323 to the IL6 receptor, which has been successfully used in clinic. Since we are developing CAR 324 T cells that recognize fungal antigens, at present we are not sure if there are any off target 325 toxicities associated with this therapy. The current studies were conducted using 326 immunosuppressive conditions by administering cyclophosphamide to eliminate the host 327 innate immune system and induce cryptococcosis. The disadvantage of this model is that no 328 information was collected on the CAR T-cell mediated activation of the host innate immune 329 system for clearing infection as well as associated toxicities such as CRS. Future studies will 330 be conducted to address these questions by developing murine homologues of GXMR-CAR and conducting studies using non-immunosuppressive conditions. The outcome of such studies 332 will provide information about the ability of GXMR-CAR T cells to clear Cryptococcus 333 infection, the participation of the host immune system in this process, and the toxicities 334 associated with this therapy. 335 336 To determine whether GXMR-CAR + or NoDNA T cells could recognize GXM, 419 GXMR-CAR + T cells that bound to GXM were identified using an anti-GXM antibody and 420 analyzed by flow cytometry. To conduct this study, the cells were incubated for 30 min with 421 or without C. neoformans polysaccharide antigens at 1:100 dilution. After washing with PBS, 422 T cells were incubated with a murine anti-GXM mAb for 1 h (EMD Millipore; cat. no. 
Materials and Methods
In vitro assay demonstrating that GXMR-CAR + T cells target C. neoformans yeast 431
Fluorescence microscopy was used to visualize the interaction between GXMR-CAR + T cells 432 (GFP + ) and heat killed C. neoformans yeast (ATCC, cat. no. 208821) . The yeast were labeled 433 with Calcofluor-white (Thermo Fischer Scientific; cat. no. L7009) according to the 434 manufacturer's instructions. GXMR-CAR + T cells and NoDNA T cells (mock-transduced cells 435 labeled with carboxyfluorescein succinimidyl ester) were cultured at a concentration of 1 × 10 6 436 cells/ml and incubated with yeast (1 × 10 5 cells/ml) at 37°C. After 24 h, the interaction between 437 GXMR-CAR + T cells (green) or NoDNA T cells (green) with C. neoformans yeast (blue) was 438 viewed under a fluorescence microscope (Leica DMI6000B) at 100× magnification. 439
440
Detection of Cryptococcus spp. in lung tissue using GMS stain and an anti-GXM 441 immunofluorescence assay 442 Gomori methenamine-silver (GMS) staining and immunofluorescence assays were performed 443 using five-micrometer lung tissue sections from mice infused with PBS, GXMR-CAR + T cells, 444 or NoDNA T cells. For immunofluorescence assay, sections were deparaffinized using a 445
Gemini AS Automated Slide Stainer (Thermo Fisher Scientific), and antigen retrieval was 446 performed by immersing slides in 10 mM citrate buffer (Genemed; cat. no. 10-0020) and 447 heating for 20 min at 95°C. Tissue sections were treated with BlockAid blocking solution 448 (Thermo Fisher Scientific; cat. no. B10710) for 30 min and incubated with an anti-GXM 449 antibody (1:100 dilution; EMD Millipore; cat. no. MABF2069) for 1 h at room temperature. 450
Samples were washed three times with PBS, incubated with anti-mouse IgG1-fluorescein 451 isothiocyanate for 45 min at room temperature (1:100 dilution; BD Pharmingen; cat. no. 452 553443), and washed three times with PBS. ProLong Gold Antifade Mountant (Invitrogen; cat. 453 no. 36935) was added to the tissue prior to sealing with a coverslip, and imaging of lung tissue 454 was performed at 400x using the Vectra ® Polaris ™ Automated Quantitative Pathology Imaging 455 System (Perkin Elmer) located at the MD Anderson Flow Cytometry and Imaging Core Facility 456 in Houston, TX. The inForm ® Tissue Finder ™ and inForm ® Cell Analysis ™ software (Perkin 457 Elmer) was utilized to quantitate the region of GXM positive staining and the total area of lung 458 tissue on each slide. To conduct the inForm analysis, the tissue was segmented using a large 459 pattern scale, fine segmentation resolution, edges were trimmed by 5 pixels, and a minimum 460 segment size of 1550, and the components for the training set were DAPI, autofluorescence, 461 and opal 520 for GXM-FITC. The tissue categories were: GXM region (red), lung tissue 462 (green), non-tissue (blue). The percentages of the "area of GXM positive staining / total area 463 of lung tissue" of each mouse per group were compared using ANOVA. Pair-wised 464 comparisons were conducted using Tukey's HSD (honestly significant difference) test. 465
Statistical significance was defined as P value < 0.05. All analyses were performed using R 466 version 3.5.1 [40] . To conduct an ImageJ analysis of the GXM positive cells in the lungs 467 detected by immunofluorescence, the images were acquired at 200× magnification using an 468
Olympus CKX41 microscope. The color threshold mode of ImageJ software was used for 469 detection of fluorescent GXM stained cells and the threshold was adjusted to include areas of 470 GXM positive cells. The analyze particles mode was applied to remove background, and the 471 area of Titan cells was obtained for each image. The results are expressed as pixels 2 and the 472 same area of the tissue was analyzed for each group. In vitro and in vivo studies demonstrate that GXMR-CAR + T cells interact with C. neoformans 730 yeast and that GXMR-CAR + T cells infused in NSG mice infected with C. neoformans 731 promoted a reduction in the number of Titan cells in the lungs. We suggest that GXMR-CAR + 732 T cells use two major mechanisms to control cryptococcosis: 1) activation of neutrophils and 733
APCs by proinflammatory mediators released by GXMR-CAR + T cells and 2) production of 734 granzyme, perforin, and granulysin by GXMR-CAR + T cells acting on the C. neoformans. 
